Researcher

    Nagib S. Dahdah , M.D.

    nagib.dahdah.hsj@ssss.gouv.qc.ca
    Nagib S. Dahdah
    Research Axis
    Metabolic Health and Complex Diseases
    Research Theme
    Cardiometabolic and vascular health: genetic and environmental approaches
    Address
    CHUSJ Office 6e bloc 9

    Phone
    514 345-4931 #2152

    Fax
    514 345-4896

    Title

    • Associate Professor, Department of Pediatrics, University of Montreal, 2002.

    Internship opportunity(ies)

    Education

    • Specialization in Pediatric Cardiology, American Board of Pediatrics, 1998.
    • Specialization in Pediatrics, American Board of Pediatrics, 1995.
    • MD, Saint-Joseph University, Beirut, Lebanon, 1988.

    Research Interests

    My main interest is in pediatric cardiology. Many aspects, such as interventional catheterization, play an important role in my career. More precisely, Kawasaki disease is the center of my clinical research. Kawasaki disease is the primary cause of acquired heart disease in the pediatric age group. This disease targets the coronary artery circulation in children between 6 months and 6 years of age. While the major consequences of Kawasaki disease are illustrated by aneurysmal dilatation of the coronary arteries and subsequent stenosis, the least alarming consequences observed during the onset of the illness may have a rather delayed impact, leading to early atherosclerotic disease in this population of patients growing both in number and age.

    In my projects, I focus on the epidemiological aspect as well as on primary and secondary prevention of the ensuing coronary pathology. A way to prevent the consequences of this disease on the coronary arteries is to establish the diagnosis as early as possible; hence, our works have allowed us to determine that the use of a blood test (NT-proBNP) clearly enhances the diagnostic certainty. From this certainty emanates the need for the appropriate treatment. In this regard, we are part of a multicentric research program studying the effect of a new treatment (Etanercept, an anti-TNF-alpha) in association with immunoglobulins.

About this page
Edited by Hoffmann Maude

Created on 9/18/2014
Alert or send a suggestion

Every dollar counts!

Thank you for your generosity.

It's people like you that allow us to accelerate research and heal more children better every year and, as such, offer among the best healthcare in the world.

It's also possible to give by mail or by calling toll-free

1-888-235-DONS (3667)

Contact Us

514 345-4931

Légal

© 2006-2014 CHU Sainte-Justine.
All rights reserved.
Terms of Use, Confidentiality, Security

Avertissement

Les informations contenues dans le site « CHU Sainte-Justine » ne doivent pas être utilisées comme un substitut aux conseils d’un médecin dûment qualifié et autorisé ou d’un autre professionnel de la santé. Les informations fournies ici le sont à des fins exclusivement éducatives et informatives.

Consultez votre médecin si vous croyez être malade ou composez le 911 pour toute urgence médicale.

CHU Sainte-Justine